{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:49:40Z","timestamp":1790822980934,"version":"4.1.0"},"reference-count":32,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bristol-Myers Squibb"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>IDH1\/2 mutations are common in acute myeloid leukemia (AML) and represent a therapeutic target. The GIMEMA AML1516 observational protocol was designed to study the prevalence of IDH1\/2 mutations and associations with clinico-biological parameters in a cohort of Italian AML patients. We analyzed a cohort of 284 AML consecutive patients at diagnosis, 139 females and 145 males, of a median age of 65 years (range: 19\u201386). Of these, 38 (14%) harbored IDH1 and 51 (18%) IDH2 mutations. IDH1\/2 mutations were significantly associated with WHO PS &gt;2 (p &lt; 0.001) and non-complex karyotype (p = 0.021) when compared to IDH1\/2-WT. Furthermore, patients with IDH1 mutations were more frequently NPM1-mutated (p = 0.007) and had a higher platelet count (p = 0.036). At relapse, IDH1\/2 mutations were detected in 6 (25%) patients. As per the outcome, 60.5% of IDH1\/2-mutated patients achieved complete remission; overall survival and event-free survival at 2 years were 44.5% and 36.1%, respectively: these rates were similar to IDH1\/2-WT. In IDH1\/2-mutated patients, high WBC proved to be an independent prognostic factor for survival. In conclusion, the GIMEMA AML1516 confirms that IDH1\/2 mutations are frequently detected at diagnosis and underlines the importance of recognizing IDH1\/2-mutated cases up-front to offer the most appropriate therapeutic strategy, given the availability of IDH1\/2 inhibitors.<\/jats:p>","DOI":"10.3390\/cancers14123012","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T09:51:11Z","timestamp":1655545871000},"page":"3012","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3531-4766","authenticated-orcid":false,"given":"Monica","family":"Messina","sequence":"first","affiliation":[{"name":"GIMEMA Foundation, 00182 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8648-885X","authenticated-orcid":false,"given":"Alfonso","family":"Piciocchi","sequence":"additional","affiliation":[{"name":"GIMEMA Foundation, 00182 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Ottone","sequence":"additional","affiliation":[{"name":"Ematologia, Dipartimento di Biomedicina e Prevenzione, Universit\u00e0 di Roma Tor Vergata, 00133 Roma, Italy"},{"name":"Neuro-Oncohematology Unit, IRCCS Fondazione Santa Lucia, 00179 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Paolini","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia \u201cSer\u00e0gnoli\u201d Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia \u201cSer\u00e0gnoli\u201d Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Lessi","sequence":"additional","affiliation":[{"name":"Ematologia ed Immunologia Clinica, Universit\u00e0 degli Studi di Padova, 1222 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Stefano","family":"Fracchiolla","sequence":"additional","affiliation":[{"name":"UOC Ematologia, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Forghieri","sequence":"additional","affiliation":[{"name":"UO Ematologia-AOU Policlinico di Modena, 41125 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4436-1310","authenticated-orcid":false,"given":"Anna","family":"Candoni","sequence":"additional","affiliation":[{"name":"Clinica Ematologica, ASUFC, Universit\u00e0 degli Studi di Udine, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-2467","authenticated-orcid":false,"given":"Andrea","family":"Mengarelli","sequence":"additional","affiliation":[{"name":"UO Ematologia-IRCCS Istituto Nazionale Tumori Tumori Regina Elena, 00128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9139-1729","authenticated-orcid":false,"given":"Maria Paola","family":"Martelli","sequence":"additional","affiliation":[{"name":"Sezione di Ematologia ed Immunologia Clinica, Universit\u00e0 degli Studi di Perugia, 06123 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0245-0553","authenticated-orcid":false,"given":"Adriano","family":"Venditti","sequence":"additional","affiliation":[{"name":"Ematologia, Dipartimento di Biomedicina e Prevenzione, Universit\u00e0 di Roma Tor Vergata, 00133 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Michele","family":"Carella","sequence":"additional","affiliation":[{"name":"Ematologia e Centro Trapianti CSE Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7926-6052","authenticated-orcid":false,"given":"Francesco","family":"Albano","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation Unit, Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari Aldo Moro, 70121 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Mancini","sequence":"additional","affiliation":[{"name":"Ospedale Niguarda Ca Granda-SC Ematologia Blocco SUD, 20162 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1334-0851","authenticated-orcid":false,"given":"Bernardi","family":"Massimo","sequence":"additional","affiliation":[{"name":"IRCCS San Raffaele Scientific Institute, 20132 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Arena","sequence":"additional","affiliation":[{"name":"GIMEMA Foundation, 00182 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Sargentini","sequence":"additional","affiliation":[{"name":"GIMEMA Foundation, 00182 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7958-4966","authenticated-orcid":false,"given":"Mariarita","family":"Scium\u00e8","sequence":"additional","affiliation":[{"name":"UOC Ematologia, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Pastore","sequence":"additional","affiliation":[{"name":"UOC Ematologia Brindisi, 72100 Brindisi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Todisco","sequence":"additional","affiliation":[{"name":"Onco-Hematology Division, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Roti","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera Universitaria di Parma, Ematologia, Universit\u00e0 di Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Siragusa","sequence":"additional","affiliation":[{"name":"U.O. di Ematologia con Trapianto-A.U. Policlinico Paolo Giaccone, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ladetto","sequence":"additional","affiliation":[{"name":"AO SS Antonio e Biagio Arrigo, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pravato","sequence":"additional","affiliation":[{"name":"Ematologia ed Immunologia Clinica, Universit\u00e0 degli Studi di Padova, 1222 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"De Bellis","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Sanitaria Universitaria Giuliano Isontina, 34148 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6954-969X","authenticated-orcid":false,"given":"Giorgia","family":"Simonetti","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6309-0515","authenticated-orcid":false,"given":"Giovanni","family":"Marconi","sequence":"additional","affiliation":[{"name":"Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori [M1] (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-5436","authenticated-orcid":false,"given":"Claudio","family":"Cerchione","sequence":"additional","affiliation":[{"name":"Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori [M1] (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fazi","sequence":"additional","affiliation":[{"name":"GIMEMA Foundation, 00182 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vignetti","sequence":"additional","affiliation":[{"name":"GIMEMA Foundation, 00182 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Amadori","sequence":"additional","affiliation":[{"name":"Ematologia, Dipartimento di Biomedicina e Prevenzione, Universit\u00e0 di Roma Tor Vergata, 00133 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1025-4210","authenticated-orcid":false,"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6164-4761","authenticated-orcid":false,"given":"Maria Teresa","family":"Voso","sequence":"additional","affiliation":[{"name":"Ematologia, Dipartimento di Biomedicina e Prevenzione, Universit\u00e0 di Roma Tor Vergata, 00133 Roma, Italy"},{"name":"Neuro-Oncohematology Unit, IRCCS Fondazione Santa Lucia, 00179 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Cancer Genome Atlas Research Network, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1200\/JCO.2010.28.2285","article-title":"Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: A study by the Acute Leukemia French Association group","volume":"28","author":"Boissel","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1038\/leu.2011.142","article-title":"Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: A study of the AML-BFM and DCOG study groups","volume":"25","author":"Damm","year":"2011","journal-title":"Leukemias"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/cr.2012.51","article-title":"The mechanisms of IDH mutations in tumorigenesis","volume":"22","author":"Ye","year":"2012","journal-title":"Cell Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1038\/s41375-021-01318-x","article-title":"Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin\/DNA damage mutations","volume":"35","author":"Simonetti","year":"2021","journal-title":"Leukemias"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/leu.2010.267","article-title":"The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia","volume":"25","author":"Chou","year":"2011","journal-title":"Leukemias"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/s41375-018-0299-2","article-title":"IDH1-R132 changes vary according to NPM1 and other mutations status in AML","volume":"33","author":"Falini","year":"2019","journal-title":"Leukemias"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/s41375-018-0026-z","article-title":"IDH1R132, IDH2R140 and IDH2R172 in AML: Different genetic landscapes correlate with outcome and may influence targeted treatment strategies","volume":"32","author":"Meggendorfer","year":"2018","journal-title":"Leukemias"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2010-03-272146","article-title":"Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia","volume":"116","author":"Thol","year":"2010","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2009-11-250878","article-title":"Acquired mutations in the genes 525 encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid 526 leukemia: Prevalence and prognostic value","volume":"116","author":"Abbas","year":"2010","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-8722-5-5","article-title":"Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients","volume":"5","author":"Chotirat","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.24072","article-title":"Characteristics, clinical outcome, and 538 prognostic significance of IDH mutations in AML","volume":"90","author":"DiNardo","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.20.01632","article-title":"Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): A single-arm, phase 1b and randomised, phase 2 trial","volume":"22","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Aguilera-Diaz, A., Vazquez, I., Ariceta, B., Ma\u00f1\u00fa, A., Blasco-Iturri, Z., Palomino-Echeverr\u00eda, S., Larrayoz, M.J., Garc\u00eda-Sanz, R., Prieto-Conde, M.I., and Del Carmen Chill\u00f3n, M. (2020). Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0227986"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"REDCap Consortium, The REDCap consortium: Building an international community of software partners","volume":"95","author":"Harris","year":"2019","journal-title":"J. Biomed. Inform."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/bloodadvances.2021004934","article-title":"Differential impact of IDH1\/2 mutational subclasses on outcome in adult AML: Results from a large multicenter study","volume":"6","author":"Middeke","year":"2022","journal-title":"Blood Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/leu.2011.215","article-title":"Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission","volume":"26","author":"Chou","year":"2012","journal-title":"Leukemias"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: A phase 1 study","volume":"137","author":"Stein","year":"2021","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-021-00604-2","article-title":"Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy","volume":"12","author":"Venugopal","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1200\/JCO.2020.38.15_suppl.7500","article-title":"A phase Ib\/II study of ivosidenib with venetoclax +\/\u2212 azacitidine in IDH1-mutated myeloid malignancies","volume":"38","author":"Lachowiez","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/12\/3012\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:34:52Z","timestamp":1760139292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/12\/3012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,18]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["cancers14123012"],"URL":"https:\/\/doi.org\/10.3390\/cancers14123012","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,18]]}}}